Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Becton Dickinson stock gains as guidance and dividend underpin valuation

AI-generated analysis

πŸ“ˆ Becton Dickinson stock closed up 2.1% at $181.59 on September 14, 2026, outperforming the S&P 500 in a weak market session.

πŸ’° The company declared a quarterly dividend of $1.05 per share with an annualized yield of approximately 2.3%.

πŸ“Š Becton Dickinson beat Q2 earnings estimates with $3.23 EPS, surpassing the consensus of $3.14 by 2.87%.

🎯 Management provided FY 2026 guidance for EPS between $12.62 and $12.72, aligning with analyst forecasts.

πŸ€– The company is deploying its Vmax 160 system to advance intelligent pharmacy automation in hospital environments.

βš–οΈ Analyst consensus rates the stock as a 'Hold' with an average price target of $187.67.

⚠️ The dividend payout ratio is approximately 126.5%, suggesting the distribution exceeds current reported earnings.

βš–οΈ A legal fair fund process is accepting claims from investors who held stock between February 2019 and February 2020.

Bullish Signals
  • Becton Dickinson shares gained 2.1% to close at $181.59, outperforming the S&P 500 which declined 0.5% in the same session.
  • The company delivered a positive earnings surprise of 2.87% in the most recent quarter with EPS of $3.23 versus an estimate of $3.14.
  • Becton Dickinson provided FY 2026 guidance for EPS between $12.62 and $12.72, which aligns closely with the average analyst forecast of $12.67.
  • The company declared a quarterly dividend of $1.05 per share, providing an annualized yield of approximately 2.3% to income-focused investors.
Risk Factors
  • The reported payout ratio is approximately 126.5%, indicating that the current dividend exceeds reported earnings and raising questions about sustainability.
  • An ongoing legal fair fund process is accepting claims from shareholders who purchased stock between February 2019 and February 2020, representing a specific risk factor.
Full Analysis
Becton, Dickinson and Company (BDX) shares rose 2.1% to close at $181.59 on the NYSE on September 14, 2026, outperforming the broader S&P 500 which fell 0.5%. The stock's gain was driven by positive earnings guidance and a declared quarterly dividend of $1.05 per share, supporting its appeal to income-focused investors. Financially, the company reported Q2 earnings of $3.23 per share, beating analyst consensus estimates of $3.14. For fiscal year 2026, BDX has provided guidance for EPS between $12.62 and $12.72, which aligns closely with the average analyst forecast of approximately $12.67. Analysts currently maintain a 'Hold' rating with an average price target of $187.67, implying potential upside from current levels. Beyond earnings, BDX continues to invest in its medical technology portfolio, specifically deploying its Vmax 160 system for intelligent pharmacy automation. The company maintains a market capitalization of approximately $49 billion. However, the stock faces headwinds regarding dividend sustainability, as the reported payout ratio stands at roughly 126.5%, indicating the current distribution exceeds reported earnings. Investors should also note ongoing legal proceedings involving the Becton Fair Fund, which is accepting claims from shareholders who purchased stock between February 2019 and February 2020. The fund is currently processing these claims with a bar date set for December 13, 2026, representing a specific risk factor within the company's broader risk profile.